ArticleEClinicalMedicine2024

Donor-derived Anti-CD19 CAR T cells GC007g for relapsed or refractory B-cell acute lymphoblastic leukemia after allogeneic HSCT: a phase 1 trial.

Yi Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.